

Specialty

Focus

Urology

Q1 2022 Acquisition Activity and Outlook

Solaris Health Continues Aggressive Growth - Adds Major Florida Partnership

The first quarter of 2022 delivered three reported urology practice acquisitions, continuing a pattern of smaller deal volume and larger deal size when compared to other practice specialties undergoing M&A consolidation.

In January, Urology America announced a new partnership with Urology Associates of Denver, adding seven urologists and two radiation oncologists serving five locations in the Denver area. The company now supports more than 55 providers in Texas and Colorado. In March, Solaris Health Holdings announced a

Eric J. Yetter


Managing Director and Healthcare Team Leader (615) 477-4741 eric.yetter@focusbankers.com

J. Andrew Snyder
Managing Director
(615) 319-3233
andy.snyder@focusbankers.com


partnership with Advanced Urology Institute (AUI), one of the largest urology practices in Florida. AUI includes 105 providers who care for over 150,000 unique patients each year.

We expect M&A activity in 2022 to remain focused on large practice (10+ physicians) partnerships as early private equity investors seek to establish platforms for growth.

12-Month Quarterly Acquisition Trend



PE Consolidation Lifecycle Positioning



Notable Deals in Q1 2022

Buyer	Practice	State	MDs	Date
Urology America	Urology Associates of Denver	CO	9	1/11/22
Solaris Health Partners	Advanced Urology Institute	FL	74	3/2/22
Regional Urology	Ochsner LSU Health	LA	10	3/8/22



Urology - Q1 2022 Acquisition Activity and Outlook

www.focusbankers.com

Legal Disclaimer/Other Disclosures

This report is for informational purposes only and does not constitute an offer, invitation, solicitation, or recommendation to buy, sell, subscribe for, or issue any securities and shall not form the basis of any contract with FOCUS Investment Banking, LLC. This report was prepared exclusively for the benefit and internal use of the person or company to whom it is directly addressed and delivered (including such recipient's subsidiaries, the "Company") in order to assist the Company in evaluating, on a preliminary basis, the feasibility of a possible transaction or transactions and does not carry any right of publication or disclosure, in whole or in part, to any other party. This report is for discussion purposes only and is incomplete without reference to, and should be viewed solely in conjunction with, the oral briefing provided by FOCUS Investment Banking, LLC ("FOCUS"). Neither this report nor any of its contents may be used for any other purpose without the prior written consent of FOCUS.

The information in this report is based upon FOCUS estimates and reflects prevailing conditions and our views as of this date, all of which are accordingly subject to change. In preparing this report, we have relied upon and assumed, without independent verification, the accuracy and completeness of information available from public sources. In addition, our analyses are not and do not purport to be appraisals of the assets, stock, or business of the Company or any other entity. FOCUS makes no representations as to the actual value which may be received in connection with a transaction or the legal, tax or accounting effects of consummating a transaction. FOCUS does not render legal or tax advice, and the information contained in this communication should not be regarded as such. The information in this report does not take into account the effects of a possible transaction (or transactions) involving an actual or potential change of control, which may have significant valuation and other effects. The information in this report is confidential.

If you are not the intended recipient or an authorized representative of the intended recipient, you are hereby notified that any review, dissemination or copying of this report is prohibited.

Copyright Notice

The contents of this paper, including (but not limited to) all written material, images, analysis, and graphics, are protected under international copyright and trademark laws. You may not copy, publish, reproduce, broadcast, modify, reprint, transmit or distribute any material from this paper or pdf in whole or in part without the express written permission of FOCUS.